Moderna's mRNA Flu Vaccine Faces FDA Advisory Panel Vote

What happened

The FDA's advisory panel will vote on whether Moderna's mRNA flu vaccine benefits outweigh risks in older adults, after the FDA reversed its earlier refusal to review the application. This vote, scheduled before the Aug 5 PDUFA date, introduces a make-or-break binary event for the stock. Moderna's Q1'26 showed $389M revenue but $1.34B net loss, with cash at $7.46B before a $950M patent settlement payment due July 8. The outcome of this panel vote will significantly impact the near-term regulatory narrative and the company's ability to diversify beyond COVID.

Implication

The FDA panel vote is a critical catalyst that could unlock the U.S. flu market for Moderna, supporting the bull case of $65. However, given the company's cash burn and pending settlement, approval alone does not fix fundamentals. The stock remains speculative until post-payment liquidity and approval are confirmed.

Thesis delta

The news adds a specific near-term catalyst (advisory panel vote) that was not explicitly modeled in the master report's 3-6 month re-assessment window. The risk of a negative panel outcome increases the probability of the bear case ($35) if the vote is negative, but a positive vote could accelerate the bull case. The thesis now includes an additional binary event before the Aug 5 PDUFA, requiring active monitoring.